2016
Survival benefits of antiretroviral therapy in Brazil: a model‐based analysis
Luz PM, Girouard MP, Grinsztejn B, Freedberg KA, Veloso VG, Losina E, Struchiner CJ, MacLean RL, Parker RA, Paltiel AD, Walensky RP. Survival benefits of antiretroviral therapy in Brazil: a model‐based analysis. Journal Of The International AIDS Society 2016, 19: 20623. PMID: 27029828, PMCID: PMC4814587, DOI: 10.7448/ias.19.1.20623.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyHIV-positive patientsSurvival benefitART initiationEligible HIV-positive patientsProvision of ARTDramatic survival benefitsSubsequent ART regimensMean CD4 countLife expectancyNumber of patientsProjected life expectancyART regimensCD4 countHigher CD4HIV diseaseRegimen efficacyLife expectancy increasesEra 1PatientsTherapyNational programExpectancyCD4Regimens
2004
A therapeutic HIV vaccine: how good is good enough?
Walensky RP, Paltiel AD, Goldie SJ, Gandhi RT, Weinstein MC, Seage GR, Smith HE, Zhang H, Freedberg KA. A therapeutic HIV vaccine: how good is good enough? Vaccine 2004, 22: 4044-4053. PMID: 15364455, DOI: 10.1016/j.vaccine.2004.03.059.Peer-Reviewed Original Research
1996
Economic Evaluation of HIV Testing Among Intravenous Drug Users: An Analytic Framework and Its Application to Italy
Villari P, Fattore G, Siegel J, Paltiel A, Weinstein M. Economic Evaluation of HIV Testing Among Intravenous Drug Users: An Analytic Framework and Its Application to Italy. International Journal Of Technology Assessment In Health Care 1996, 12: 336-357. PMID: 8707505, DOI: 10.1017/s0266462300009673.Peer-Reviewed Original ResearchConceptsIntravenous drug usersEarly treatmentDrug usersHIV testing programsLife expectancyEffective early treatmentLow prevalence scenariosHealth care interventionsYears of lifeCost-effectiveness analysisHIV testingAsymptomatic subjectsCare interventionsPrevalence areasHigh prevalenceEconomic evaluationCost-effective procedureHIVPrevalenceTreatmentMore evidenceBehavior changeExpectancyCost savingsCohort